… Lower-risk myelodysplastic syndromes (MDSs) are defined as having low or intermediate
1 risk by the International Prognostic Scoring System and are characterized mainly by anemia …

… Higher-risk myelodysplastic syndromes (MDS) are defined by patients who fall into higher-risk …
Higher-risk eligible patients should be offered consultation to discuss hematopoietic stem …

… Treatment of patients with lower-risk myelodysplastic syndromes, especially for anaemia,
includes growth factors, lenalidomide, and transfusions. Treatment of higher-risk patients is …

… Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that
of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a …

… Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk
myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57. …

… The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders
characterized by peripheral blood cytopenias and increased risk of transformation to acute …

… I consider the use of lower doses of 5-azacitidine in patients at high risk for relapse post
transplantation, including more recently now those with higher risk mutations such as p53 or …

… Efficacy of azacitidine compared with that of conventional care regimens in the treatment
of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. …

… Myelodysplastic syndromes comprise a very heterogeneous group of myeloid malignancies
with very distinct natural histories. Myelodysplastic syndromes occur in three to four …

… in higher risk MDS. This paper reviews the various therapeutic options for higher risk MDS,
… This paper reviews the therapeutic options for higher risk MDS, providing rationale for …